MIP Discovery


Cell and gene therapies offer exciting new possibilities for curing diseases and improving quality of life. Viral vectors are critical components for many such therapies; however the underlying technologies used to design and manufacture these components is not yet at the required standard in terms of scale, performance or economics. MIP Discovery has identified critical challenges present during the development and manufacture of viral vectors. In response to these, we are developing synthetic affinity reagents that offer an alternative approach to detection, capture and purification of challenging target molecules, including Endotoxins, residual PEI, VSV-G and AAV capsids. Our unique, animal free solutions can withstand extreme temperatures and caustic environments, and have been exemplified in ELISA, BLI, magnetic resins and chromatography applications.

Based in

Created in

> Website


#Biotech 02.2024


Mercia Ventures, Calculus Capital & Angels